Naloxone Accord (Naloxone Hydrochloride)

Naloxone blocks the mu, kappa and delta opioid receptors by binding to them with higher affinity than most opioid agonists. This competitive antagonism displaces the opioids from the receptors, stopping their effects and allowing normal respiratory and central nervous system function to resume.

The dose of Naloxone Accord is determined by the prescribing clinician based on the severity of the opioid exposure, the route of administration, and the patient’s clinical response. Healthcare professionals follow local protocols and adjust dosing as needed.

Safety data for naloxone in pregnancy and lactation are limited. It is generally considered low risk because it does not cross the placenta in significant amounts, but the decision to use it should be made by a qualified healthcare provider weighing potential benefits and risks.

To order Naloxone Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Naloxone is the most widely used opioid antagonist due to its rapid onset and short duration of action, making it ideal for emergency reversal. Alternatives such as nalmefene have a longer half‑life but a slower onset. Choice of agent depends on clinical scenario, availability and specific patient factors.

Naloxone Accord should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Do not freeze the product. Maintaining these conditions preserves its potency and sterility until the point of use.

Naloxone Accord is administered by a healthcare professional via intramuscular or intravenous injection. The appropriate route and dose are selected based on the patient’s condition, and the drug is typically given as a rapid bolus followed by additional doses if necessary.

The most serious risks include severe hypotension, cardiac arrest, pulmonary edema, seizures, and anaphylactic reactions. These events are rare but require immediate medical attention and monitoring, especially in patients with underlying cardiovascular disease.

Naloxone Accord is contraindicated in individuals with known hypersensitivity to naloxone or any component of the formulation. It should also be used with caution in patients with severe cardiovascular disease, and it is not intended for routine use in patients who are not experiencing opioid toxicity.